RecruitingNCT06025903
Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis
Sponsor
IRCCS San Raffaele
Enrollment
140 participants
Start Date
Sep 20, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this project is to study genetic determinants of mitochondrial impairment in primary progressive multiple sclerosis. Specific aims are: 1) identify mitochondrial-related pathways, inherited and somatic mitochondrial DNA mutations associated to primary progressive multiple sclerosis, 2) functionally assess the identified genetic alterations.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patients affected by primary progressive or relapsing remitting multiple sclerosis
- Patient able to provide informed consent
Exclusion Criteria2
- Individuals with \< 18 years
- Patients not affected by primary progressive or relapsing remitting multiple sclerosis
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06025903
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT072071481 location